Comparison of triazolam and placebo in the treatment of insomnia in depressed patients

R. A. Dominguez, A. F. Jacobson, B. J. Goldstein, R. M. Steinbook

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

A 4-week double-blind study compared triazolam and placebo in 78 depressed outpatients receiving imipramine. The diagnosis of major depressive disorder was established using DSM-III criteria. The baseline mean total score on the Hamilton Depression Rating Scale was over 26 for both groups. The imipramine dosage ranged from 50 to 300 milligrams per day. Patients were randomized to receive, along with imipramine, either triazolam 0.5 mg or placebo at night for 28 consecutive nights. Although insomnia improved in both the placebo and triazolam groups, the triazolam group showed significantly more improvement than the control group in most sleep parameters. Depressive symptoms improved equally and significantly for both groups; by week 4 the mean Hamilton Depression Rating Scale scores were 12.3 for both groups. Of the patients who dropped out of treatment because of side effects, twice as many were on placebo as on triazolam. The study results show triazolam to be effective in treating insomnia in depressed patients without diminishing the therapeutic effect of imipramine.

Original languageEnglish
Pages (from-to)856-865
Number of pages10
JournalCurrent Therapeutic Research - Clinical and Experimental
Volume36
Issue number5 I
StatePublished - Dec 1 1984
Externally publishedYes

Fingerprint

Triazolam
Sleep Initiation and Maintenance Disorders
Imipramine
Placebos
Depression
Therapeutics
Major Depressive Disorder
Therapeutic Uses
Double-Blind Method
Diagnostic and Statistical Manual of Mental Disorders
Sleep
Outpatients
Control Groups

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dominguez, R. A., Jacobson, A. F., Goldstein, B. J., & Steinbook, R. M. (1984). Comparison of triazolam and placebo in the treatment of insomnia in depressed patients. Current Therapeutic Research - Clinical and Experimental, 36(5 I), 856-865.

Comparison of triazolam and placebo in the treatment of insomnia in depressed patients. / Dominguez, R. A.; Jacobson, A. F.; Goldstein, B. J.; Steinbook, R. M.

In: Current Therapeutic Research - Clinical and Experimental, Vol. 36, No. 5 I, 01.12.1984, p. 856-865.

Research output: Contribution to journalArticle

Dominguez, RA, Jacobson, AF, Goldstein, BJ & Steinbook, RM 1984, 'Comparison of triazolam and placebo in the treatment of insomnia in depressed patients', Current Therapeutic Research - Clinical and Experimental, vol. 36, no. 5 I, pp. 856-865.
Dominguez, R. A. ; Jacobson, A. F. ; Goldstein, B. J. ; Steinbook, R. M. / Comparison of triazolam and placebo in the treatment of insomnia in depressed patients. In: Current Therapeutic Research - Clinical and Experimental. 1984 ; Vol. 36, No. 5 I. pp. 856-865.
@article{0876fe4b798c42868dc80ca2f2d40a0d,
title = "Comparison of triazolam and placebo in the treatment of insomnia in depressed patients",
abstract = "A 4-week double-blind study compared triazolam and placebo in 78 depressed outpatients receiving imipramine. The diagnosis of major depressive disorder was established using DSM-III criteria. The baseline mean total score on the Hamilton Depression Rating Scale was over 26 for both groups. The imipramine dosage ranged from 50 to 300 milligrams per day. Patients were randomized to receive, along with imipramine, either triazolam 0.5 mg or placebo at night for 28 consecutive nights. Although insomnia improved in both the placebo and triazolam groups, the triazolam group showed significantly more improvement than the control group in most sleep parameters. Depressive symptoms improved equally and significantly for both groups; by week 4 the mean Hamilton Depression Rating Scale scores were 12.3 for both groups. Of the patients who dropped out of treatment because of side effects, twice as many were on placebo as on triazolam. The study results show triazolam to be effective in treating insomnia in depressed patients without diminishing the therapeutic effect of imipramine.",
author = "Dominguez, {R. A.} and Jacobson, {A. F.} and Goldstein, {B. J.} and Steinbook, {R. M.}",
year = "1984",
month = "12",
day = "1",
language = "English",
volume = "36",
pages = "856--865",
journal = "Current Therapeutic Research",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "5 I",

}

TY - JOUR

T1 - Comparison of triazolam and placebo in the treatment of insomnia in depressed patients

AU - Dominguez, R. A.

AU - Jacobson, A. F.

AU - Goldstein, B. J.

AU - Steinbook, R. M.

PY - 1984/12/1

Y1 - 1984/12/1

N2 - A 4-week double-blind study compared triazolam and placebo in 78 depressed outpatients receiving imipramine. The diagnosis of major depressive disorder was established using DSM-III criteria. The baseline mean total score on the Hamilton Depression Rating Scale was over 26 for both groups. The imipramine dosage ranged from 50 to 300 milligrams per day. Patients were randomized to receive, along with imipramine, either triazolam 0.5 mg or placebo at night for 28 consecutive nights. Although insomnia improved in both the placebo and triazolam groups, the triazolam group showed significantly more improvement than the control group in most sleep parameters. Depressive symptoms improved equally and significantly for both groups; by week 4 the mean Hamilton Depression Rating Scale scores were 12.3 for both groups. Of the patients who dropped out of treatment because of side effects, twice as many were on placebo as on triazolam. The study results show triazolam to be effective in treating insomnia in depressed patients without diminishing the therapeutic effect of imipramine.

AB - A 4-week double-blind study compared triazolam and placebo in 78 depressed outpatients receiving imipramine. The diagnosis of major depressive disorder was established using DSM-III criteria. The baseline mean total score on the Hamilton Depression Rating Scale was over 26 for both groups. The imipramine dosage ranged from 50 to 300 milligrams per day. Patients were randomized to receive, along with imipramine, either triazolam 0.5 mg or placebo at night for 28 consecutive nights. Although insomnia improved in both the placebo and triazolam groups, the triazolam group showed significantly more improvement than the control group in most sleep parameters. Depressive symptoms improved equally and significantly for both groups; by week 4 the mean Hamilton Depression Rating Scale scores were 12.3 for both groups. Of the patients who dropped out of treatment because of side effects, twice as many were on placebo as on triazolam. The study results show triazolam to be effective in treating insomnia in depressed patients without diminishing the therapeutic effect of imipramine.

UR - http://www.scopus.com/inward/record.url?scp=0021746476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021746476&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 856

EP - 865

JO - Current Therapeutic Research

JF - Current Therapeutic Research

SN - 0011-393X

IS - 5 I

ER -